Initial Public Offering Completed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both hematological and solid tumor programs Leadership strengthened through key management and board appointments UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers ...

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results GlobeNewswire May 20, 2021 IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics...

LAVA Therapeutics BV: LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results Clinical development plans on schedule in both hematological and solid tumor programs Leadership strengthened through key management and board appointments UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers (bsTCEs) to transform cancer therapy, today reported its business update and first quarter 2021 financial results. "We ...